MAOB and Alzheimer disease: In addition, in vivo blocking studies with oral selegiline and rasagiline revealed specific binding of [18F]THK-5351 to MAO-B in AD and PSP brains (Ng et al., 2017, 2019), where [18F]THK-5351 binding was reduced on average by 37–52% in the post-selegiline scans and 53–89% in the post-rasagiline scans (Ng et al., 2017, 2019).